{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:01:17Z","timestamp":1793037677000,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A novel dopamine-receptor small molecule inhibitor, ONC201, was observed to elicit a treatment response in patients with H3K27M-altered diffuse midline gliomas (DMG). Given restricted access to this therapy, an alternative formulation from Germany (GsONC201) was made available by compassionate means. We describe the treatment outcomes of these patients and our experience with GsONC201.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multicenter retrospective study of adult Chinese patients with histologically confirmed H3K727M-altered DMG. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival, the observed response rate (ORR) at 3 months after radiotherapy and GsONC201-associated adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-seven patients, median age of 40 years (range: 31-52), were identified. Fifty-two percent (14\/27) of tumors arose from the thalamus followed by the pons (22%, 6). Eighty-five percent (23\/27) of patients received standard-of-care (SOC) fractionated radiotherapy. Thirty-seven percent (10\/27) of patients received GsONC201 of which 80% (8\/10) started it as first-line monotherapy after SOC. The mOS of the entire cohort was 17.4 months (IQR: 12.1-30.0). GsONC201\u2009+\u2009SOC patients (8) had a mOS of 18.9 months (IQR: 11.3-54.4) compared to 16.0 months (IQR: 12.5-27.6) for SOC-alone patients (13, P value: .57). The ORR was 33% (7\/21) and 63% of GsONC201\u2009+\u2009SOC patients had a treatment response compared to 15% of SOC-alone patients (P value: .01). No GsONC201-associated adverse effects were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first real-world study to review the outcomes of first-line imipridone-class agent therapy in adult Chinese DMG patients. GsONC201 was well-tolerated, but its effect on OS remains unknown.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag074","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:57:35Z","timestamp":1773838655000},"source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of H3K27M-altered diffuse midline glioma adult Chinese patients and real-world experience with German-sourced ONC201 targeted therapy: A multi-center study in Hong Kong"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7345-7904","authenticated-orcid":false,"given":"Peter Y M","family":"Woo","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Prince of Wales Hospital ,","place":["Hong Kong"]},{"name":"Otto Wong Brain Tumour Centre, The Chinese University of Hong Kong ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara K W","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Princess Margaret Hospital ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai-Fung","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Queen Mary Hospital ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor K H","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Prince of Wales Hospital ,","place":["Hong Kong"]},{"name":"Otto Wong Brain Tumour Centre, The Chinese University of Hong Kong ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny T M","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Prince of Wales Hospital ,","place":["Hong Kong"]},{"name":"Otto Wong Brain Tumour Centre, The Chinese University of Hong Kong ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W Y","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony K T","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Princess Margaret Hospital ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree K K","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Queen Elizabeth Hospital ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce S W","family":"Chow","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Queen Elizabeth Hospital ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M K","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K H","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa P K","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie M W","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kwong Wah Hospital ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Man","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus K C","family":"Leung","sequence":"additional","affiliation":[{"name":"AMO Oncology Centre ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C W","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert H F","family":"Loong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, The Chinese University of Hong Kong ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Sang","family":"Poon","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Prince of Wales Hospital ,","place":["Hong Kong"]},{"name":"Otto Wong Brain Tumour Centre, The Chinese University of Hong Kong ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"El-Helali","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, The University of Hong Kong ,","place":["Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"2026041908165930200_vdag074-B1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"2026041908165930200_vdag074-B2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026041908165930200_vdag074-B3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","article-title":"K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas","volume":"124","author":"Khuong-Quang","year":"2012","journal-title":"Acta Neuropathol"},{"key":"2026041908165930200_vdag074-B4","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1093\/neuonc\/noad164","article-title":"H3K27M mutant glioma: disease definition and biological underpinnings","volume":"26","author":"Saratsis","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026041908165930200_vdag074-B5","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1093\/neuonc\/noad220","article-title":"H3 K27M-altered glioma and diffuse intrinsic pontine glioma: semi-systematic review of treatment landscape and future directions","volume":"26","author":"van den Bent","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026041908165930200_vdag074-B6","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.wneu.2023.07.001","article-title":"Prognostic indicators for H3K27M-Mutant diffuse midline glioma: a population-based retrospective surveillance, epidemiology, and end results database analysis","volume":"178","author":"Adhikari","year":"2023","journal-title":"World Neurosurg"},{"key":"2026041908165930200_vdag074-B7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-019-03271-3","article-title":"Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201","volume":"145","author":"Chi","year":"2019","journal-title":"J Neurooncol"},{"key":"2026041908165930200_vdag074-B8","doi-asserted-by":"publisher","first-page":"115165","DOI":"10.1016\/j.ejca.2024.115165","article-title":"Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: results of an international academia-driven compassionate use program","volume":"216","author":"Di Carlo","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026041908165930200_vdag074-B9","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1158\/2159-8290.CD-23-0131","article-title":"Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways","volume":"13","author":"Venneti","year":"2023","journal-title":"Cancer Discov"},{"key":"2026041908165930200_vdag074-B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-015-0346-9","article-title":"Identification of TRAIL-inducing compounds highlights small molecule ONC201\/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway","volume":"14","author":"Allen","year":"2015","journal-title":"Mol Cancer"},{"key":"2026041908165930200_vdag074-B11","doi-asserted-by":"publisher","first-page":"74380","DOI":"10.18632\/oncotarget.11814","article-title":"Discovery and clinical introduction of first-in-class imipridone ONC201","volume":"7","author":"Allen","year":"2016","journal-title":"Oncotarget"},{"key":"2026041908165930200_vdag074-B12","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/neuonc\/noac041","article-title":"Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas","volume":"24","author":"Przystal","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026041908165930200_vdag074-B13","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1093\/neuonc\/noae031","article-title":"ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma","volume":"26","author":"Arrillaga-Romany","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026041908165930200_vdag074-B14","doi-asserted-by":"publisher","first-page":"vdab169","DOI":"10.1093\/noajnl\/vdab169","article-title":"Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma","volume":"3","author":"Duchatel","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2026041908165930200_vdag074-B15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11060-023-04347-x","article-title":"Preliminary findings of German-sourced ONC201 treatment in H3K27 altered pediatric pontine diffuse midline gliomas","volume":"163","author":"Tanr\u0131kulu","year":"2023","journal-title":"J Neurooncol"},{"key":"2026041908165930200_vdag074-B16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/nop\/npac069","article-title":"Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period","volume":"10","author":"Woo","year":"2023","journal-title":"Neurooncol Pract"},{"key":"2026041908165930200_vdag074-B17","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"key":"2026041908165930200_vdag074-B18","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026041908165930200_vdag074-B19","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041908165930200_vdag074-B20","author":"Diagnosis DoCTa","year":"2025"},{"key":"2026041908165930200_vdag074-B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14791\/btrt.2021.9.e8","article-title":"The Korean Society for Neuro-Oncology (KSNO) guideline for adult diffuse midline glioma: version 2021.1","volume":"9","author":"Yoon","year":"2021","journal-title":"Brain Tumor Res Treat"},{"key":"2026041908165930200_vdag074-B22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/neuonc\/now101","article-title":"Pediatric high-grade glioma: biologically and clinically in need of new thinking","volume":"19","author":"Jones","year":"2017","journal-title":"Neuro Oncol"},{"key":"2026041908165930200_vdag074-B23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.prro.2024.04.013","article-title":"An update on H3K27M-altered diffuse midline glioma: diagnostic and therapeutic challenges in clinical practice","volume":"14","author":"Akdemir","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"2026041908165930200_vdag074-B24","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3389\/fonc.2019.01568","article-title":"MGMT expression contributes to temozolomide resistance in H3K27M-Mutant diffuse midline gliomas","volume":"9","author":"Abe","year":"2019","journal-title":"Front Oncol"},{"key":"2026041908165930200_vdag074-B25","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/14728222.2023.2277232","article-title":"Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies","volume":"27","author":"Rechberger","year":"2023","journal-title":"Expert Opin Ther Targets"},{"key":"2026041908165930200_vdag074-B26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40478-022-01336-5","article-title":"A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis","volume":"10","author":"Dhar","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"2026041908165930200_vdag074-B27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nm.4296","article-title":"Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas","volume":"23","author":"Piunti","year":"2017","journal-title":"Nat Med"},{"key":"2026041908165930200_vdag074-B28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/neuonc\/noaf097","article-title":"H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition","volume":"27","author":"Guo","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026041908165930200_vdag074-B29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI174794","article-title":"BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma","volume":"134","author":"Watanabe","year":"2024","journal-title":"J Clin Invest"},{"key":"2026041908165930200_vdag074-B30","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/s41591-023-02555-6","article-title":"A H3K27M-targeted vaccine in adults with diffuse midline glioma","volume":"29","author":"Grassl","year":"2023","journal-title":"Nat Med"},{"key":"2026041908165930200_vdag074-B31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/neuonc\/noz164","article-title":"Biological activity of weekly ONC201 in adult recurrent glioblastoma patients","volume":"22","author":"Arrillaga-Romany","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026041908165930200_vdag074-B32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40425-019-0599-8","article-title":"Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration","volume":"7","author":"Stein","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026041908165930200_vdag074-B33","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.23.01134","article-title":"ONC201 (dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma","volume":"42","author":"Arrillaga-Romany","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026041908165930200_vdag074-B34","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3171\/2019.2.PEDS18480","article-title":"First clinical experience with DRD2\/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report","volume":"23","author":"Hall","year":"2019","journal-title":"J Neurosurg Pediatr"},{"key":"2026041908165930200_vdag074-B35","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/0008-5472.CAN-23-0186","article-title":"ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma","author":"Jackson","year":"2023","journal-title":"Cancer Res"},{"key":"2026041908165930200_vdag074-B36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/nox149","article-title":"Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location","volume":"20","author":"Karremann","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026041908165930200_vdag074-B37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.humpath.2018.04.015","article-title":"H3 K27M-mutant diffuse midline gliomas in different anatomical locations","volume":"78","author":"Wang","year":"2018","journal-title":"Hum Pathol"},{"key":"2026041908165930200_vdag074-B38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132107","article-title":"Prognostic features of recurrent midline and H3 K27M-mutant glioma","volume":"17","author":"Bagley","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026041908165930200_vdag074-B39","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s10072-020-04489-0","article-title":"Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?","volume":"42","author":"Manjunath","year":"2021","journal-title":"Neurol Sci"},{"key":"2026041908165930200_vdag074-B40","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1111\/cns.14307","article-title":"Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma","volume":"29","author":"Gong","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"2026041908165930200_vdag074-B41","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00401-015-1478-0","article-title":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes","volume":"130","author":"Castel","year":"2015","journal-title":"Acta Neuropathol"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag074\/67457992\/vdag074.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag074\/67457992\/vdag074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag074\/67457992\/vdag074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T12:17:06Z","timestamp":1776601026000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag074\/8533559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag074","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag074"}}